Answers are grounded in this paper and cite their sources.
Prospective case series evaluates cannabidiol effectiveness in drug-resistant epilepsy, suggesting selective benefits for specific subgroups.
Objective: Cannabidiol (CBD) has demonstrated efficacy in selected developmental and epileptic encephalopathies (DEEs), but phenotype-specific response in real-world practice remains uncertain. We prospectively evaluated the clinical effectiveness of adjunctive CBD in children and young adults with drug-resistant epilepsy (DRE), focusing on patient subgroups most likely to benefit. Methods: In a prospective observational case series, 13 patients (children and young adults) with DRE received adjunctive CBD and were followed for seizure outcomes at 3 months. Epilepsy etiology, seizure type, baseline frequency, CBD dose, treatment response, and adverse effects were recorded. Response was defined as ≥ 50% reduction in seizure frequency. Results: Five of 13 (38.5%) patients demonstrated ≥ 50% seizure reduction. Marked improvement (∼90%) occurred in three, and moderate improvement (> 50%) in two, predominantly among DEEs (including generalized network epilepsies and West–to–Lennox–Gastaut evolution). In contrast, no meaningful benefit was observed in focal structural epilepsies, despite doses up to 20 mg/kg/day. Sedation and behavioral changes were the most common adverse effects. Conclusion: In this prospective cohort, CBD showed selective efficacy in DEEs, while focal structural epilepsies were largely nonresponsive, supporting a syndrome/phenotype-stratified approach to CBD use in DRE. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: